Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiomyocyte-Specific Smad7 Protects the Pressure-Overloaded Heart, Inhibiting the Transforming Growth Factor-β Receptor 1/Smad2/3 Cascade.

Journal of the American Heart Association·2026
Same author

Restraining fibrosis in cardiac repair.

Cardiovascular research·2026
Same author

LepR+ Fibroblasts in Maladaptive Cardiac Fibrosis: Mechanisms and Controversies.

Circulation research·2026
Same author

Artificial Intelligence Applications in Cardiac MR Imaging.

Magnetic resonance imaging clinics of North America·2026
Same author

Revisiting the role of periostin in cardiac repair.

American journal of physiology. Heart and circulatory physiology·2026
Same author

Animal Models in Biomedical Research: Realities, Misconceptions, and Controversies.

JACC. Basic to translational science·2026

Related Experiment Video

Updated: May 10, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Targeting inflammatory pathways in myocardial infarction.

Panagiota Christia1, Nikolaos G Frangogiannis

  • 1Department of Medicine, Albert Einstein College of Medicine, The Wilf Family Cardiovascular Research Institute, Bronx, NY, USA.

European Journal of Clinical Investigation
|June 19, 2013
PubMed
Summary
This summary is machine-generated.

Inflammation after heart attack drives damaging ventricle remodeling and heart failure. Suppressing this post-infarction inflammation may protect the heart, but targeted therapies are needed based on patient inflammatory responses.

Keywords:
Animal modelscytokineinflammationleucocytesmyocardial infarctionremodelling

More Related Videos

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

Related Experiment Videos

Last Updated: May 10, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Pathophysiology

Background:

  • Acute myocardial infarction triggers cardiomyocyte necrosis, releasing damage-associated molecular patterns (DAMPs).
  • DAMPs activate inflammatory pathways, including complement and Toll-Like Receptor (TLR)/Interleukin (IL)-1 signaling, leading to intense inflammation.
  • This inflammatory response clears dead cells but also drives ventricular remodeling and heart failure progression.

Purpose of the Study:

  • To discuss the cellular and molecular events of post-infarction inflammation.
  • To identify therapeutic targets for modulating the inflammatory response after myocardial infarction.
  • To explore personalized, biomarker-based approaches for treating post-infarction remodeling.

Main Methods:

  • Review of basic cellular and molecular events in post-infarction inflammation.
  • Analysis of experimental evidence regarding inflammation's role in myocardial infarction.
  • Discussion of therapeutic strategies, including anti-integrin and anti-inflammatory approaches.

Main Results:

  • Unrestrained inflammation accentuates matrix degradation and cardiomyocyte apoptosis, contributing to dilative remodeling.
  • Failure of anti-integrin therapies suggests inflammation's role is primarily in matrix degradation, not ischemic cell death.
  • Personalized approaches are necessary due to the complexity of post-infarction remodeling.

Conclusions:

  • Timely suppression of post-infarction inflammation is crucial for myocardial protection.
  • Inhibition of pro-inflammatory signals (e.g., IL-1, MCP-1) may benefit patients with defective inflammation resolution and dilative remodeling.
  • Anti-transforming growth factor (TGF) strategies could benefit patients with hypertrophic/fibrotic responses.